SparingVision Strengthens Management Team

Paris, October 29, 2020 – SparingVision (the “Company”), a genomic medicine company focused on ocular diseases, today announces the strengthening of its senior management team with the appointment of Dr. Florence Lorget as Chief Development Sciences Officer (“CDSO”) and Dr. Rajiv Gangurde as Chief Technology Officer (“CTO”).

As CDSO, Dr. Florence Lorget will head the translational research and development sciences groups of the Company. As such, she will be leading the Company’s nonclinical studies and notably, will conduct IND/CTA regulatory activities for SPVN06, SparingVision’s lead product candidate for the treatment of Retinitis Pigmentosa (RP).

From 2018 to 2020, Dr. Lorget was the Senior Director of Nonclinical Safety Evaluation at Sangamo Therapeutics, an American genomic medicine company, where she led the translational pharmacology team and oversaw pharmacology, toxicology and PK activities for a large portfolio of gene editing, gene regulation and gene therapy programs in various therapeutic areas. For five years prior to joining Sangamo, she was a Senior Scientist in the Safety Assessment department at Genentech, where she worked as the Toxicology Therapeutic Area Lead for Ophthalmology and led the Ocular Platform team. Prior to that, Dr. Lorget was a Senior Pharmacologist/Toxicologist at BioMarin. She started her career at Amgen. Dr. Lorget has a Masters in Bioengineering from the University of Technology of Compiegne (France), a Pharm.D. and a Ph.D. in Cellular and Molecular Biology from the University of Picardie- Jules Verne (France). She completed her postdoctoral research at the University of California San Francisco (UCSF) and at the Nestle Research Center. Dr. Lorget has also been a Diplomate of the American Board of Toxicology since 2014.

As CTO, Dr. Rajiv Gangurde will lead SparingVision’s technical operations, including process and analytical development, cGMP manufacturing and quality assurance. As such, he will be leading the production activities to supply clinical trial material as well as the development of a commercial manufacturing process for SPVN06.

Dr. Gangurde joins SparingVision with over 14 years of industry experience in biopharmaceutical development, garnered mainly from his time at the biotechnology hub in Massachusetts, U.S.A. Most recently, he served as Senior Director and Head of Chemistry, Manufacturing and Controls (“CMC”) at Voyager Therapeutics, a gene therapy company based in Cambridge, MA. In this role, Dr. Gangurde was responsible for CMC strategy and management of the company’s entire gene therapy portfolio. Prior to Voyager, Dr. Gangurde was Director of Bioprocess Development & Manufacturing at Genocea Biosciences, where he led upstream and downstream process development and biochemistry groups for early- and late-stage recombinant-protein-based therapeutic vaccines. Prior to Genocea, Dr. Gangurde was Head of Protein Sciences at LakePharma (previously called, Blue Sky Bioservices), leading therapeutic protein production efforts for pre-clinical studies.